Research ArticleCancer

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

See allHide authors and affiliations

Science Translational Medicine  03 Jan 2018:
Vol. 10, Issue 422, eaao1641
DOI: 10.1126/scitranslmed.aao1641

Article Information

vol. 10 no. 422

Print ISSN: 
Online ISSN: 
  • Received for publication March 29, 2017
  • Resubmitted June 20, 2017
  • Accepted for publication November 9, 2017

Author Information

  1. Marie-Claude Bourgeois-Daigneault1,2,*,
  2. Dominic Guy Roy1,2,,
  3. Amelia Sadie Aitken1,2,,
  4. Nader El Sayes1,2,,
  5. Nikolas Tim Martin1,2,
  6. Oliver Varette1,2,
  7. Theresa Falls1,
  8. Lauren Elizabeth St-Germain1,
  9. Adrian Pelin1,2,
  10. Brian Dennis Lichty3,
  11. David Francis Stojdl2,4,
  12. Guy Ungerechts1,
  13. Jean-Simon Diallo1,2 and
  14. John Cameron Bell1,2,*
  1. 1Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.
  2. 2Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada.
  3. 3Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton L8S 4K1, Canada.
  4. 4Children’s Hospital of Eastern Ontario Research Institute, Ottawa K1H 8L1, Canada.
  1. *Corresponding author. Email: mbourgeois{at} (M.-C.B.-D.); jbell{at} (J.C.B.)
    • These authors contributed equally to this work.


    Article usage

    Article usage: December 2017 to March 2018

    Dec 2017111
    Jan 2018111995781421
    Feb 20181352149468
    Mar 201865853139